Semaglutide

Semaglutide belongs to a class of medications called GLP-1 receptor agonists ^{[1, 2, 3]}. GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces in the gut after eating. Semaglutide mimics this hormone but lasts much longer in the body — about one week compared to a few minutes for natural GLP-1 ^[1].

When you eat, semaglutide activates GLP-1 receptors throughout your body, triggering several beneficial effects:

Blood sugar regulation: Semaglutide signals your pancreas to release more insulin when blood sugar is high, while reducing the release of glucagon (a hormone that raises blood sugar) ^{[1, 3]}. This dual action helps keep blood sugar levels in a healthy range without causing dangerously low blood sugar on its own.

Slowed digestion: The medication slows how quickly food moves from your stomach into your small intestine ^[1]. This means sugar from meals enters your bloodstream more gradually, preventing the sharp blood sugar spikes that occur after eating.

Appetite reduction: Semaglutide acts on appetite centers in the brain, particularly the hypothalamus ^{[1, 9]}. Most people experience noticeably reduced hunger and feel satisfied with smaller portions. This is the primary mechanism behind its weight loss effects.

Heart benefits: Clinical trials have shown that semaglutide reduces the risk of major cardiovascular events (heart attack, stroke, and cardiovascular death) in people with type 2 diabetes and established heart disease ^[5]. The SELECT trial further demonstrated cardiovascular risk reduction in overweight/obese adults without diabetes ^[8]. The exact mechanism is not fully understood but may involve improvements in inflammation, blood pressure, and lipid levels ^{[5, 8]}.

Starting semaglutide is a gradual process. Your doctor will begin you on the lowest dose and slowly increase it over several weeks to months ^{[1, 2, 3]}. This approach helps your body adjust and minimizes side effects.

First 1-4 weeks (starting dose): Most people begin noticing reduced appetite within the first week or two ^[10]. Some experience mild nausea, which is the most common early side effect ^[1]. Eating smaller meals and avoiding fatty or greasy foods can help. You may notice modest weight changes during this period.

Weeks 4-12 (dose escalation): As your dose increases, appetite suppression typically becomes more pronounced ^{[1, 4]}. Nausea may briefly return after each dose increase but usually improves within a few days. Many people report feeling full faster during meals and having less interest in snacking between meals. Blood sugar improvements are often measurable by this point ^{[10, 11]}.

Months 3-6 (maintenance dose): By now most people have reached their target dose and side effects have typically stabilized ^[1]. Weight loss becomes more consistent, averaging 1-2 pounds per week for those using the weight management dose ^[4]. Blood sugar control continues to improve. Energy levels often increase as weight decreases.

Long-term: Semaglutide is intended for ongoing use. Research shows that stopping the medication typically leads to gradual weight regain and return of elevated blood sugar levels ^[7]. The STEP 4 trial specifically demonstrated significant weight regain after discontinuation of semaglutide 2.4 mg ^[7]. Your healthcare provider will monitor your progress with regular blood tests (HbA1c) and adjust treatment as needed ^[9].

Semaglutide does not have strict food restrictions, but dietary choices can significantly affect how well you tolerate the medication ^{[1, 2, 3]}.

Food considerations: Eating large, fatty, or greasy meals may worsen nausea and other GI side effects ^[1]. Most patients find they tolerate smaller, more frequent meals better than large portions. The oral formulation (Rybelsus) must be taken on an empty stomach with no more than 4 ounces of plain water, at least 30 minutes before the first food, drink, or other oral medications of the day ^[3].

Alcohol: While there is no absolute contraindication, alcohol can worsen nausea and GI side effects ^{[1, 2]}. In patients with type 2 diabetes, alcohol can cause unpredictable blood sugar changes — both highs and lows. Heavy alcohol consumption also increases the risk of pancreatitis, which is already an uncommon but serious risk with semaglutide ^[1]. Moderate alcohol intake (if any) is advisable.

Grapefruit: No known interaction between semaglutide and grapefruit juice ^[1].

Semaglutide dosing varies by formulation and indication. All doses should be prescribed and adjusted by a healthcare provider ^{[1, 2, 3]}.

Ozempic (subcutaneous injection for type 2 diabetes) [1]: - Starting dose: 0.25 mg once weekly for 4 weeks (dose escalation, not therapeutic) - Increase to: 0.5 mg once weekly for at least 4 weeks - If additional blood sugar control is needed: 1 mg once weekly for at least 4 weeks - Maximum dose: 2 mg once weekly - Inject in abdomen, thigh, or upper arm; rotate injection sites

Wegovy (subcutaneous injection for chronic weight management) [2]: - Month 1: 0.25 mg once weekly - Month 2: 0.5 mg once weekly - Month 3: 1 mg once weekly - Month 4: 1.7 mg once weekly - Month 5 and beyond: 2.4 mg once weekly (maintenance dose) - If you do not tolerate a dose increase, your doctor may extend the escalation period

Rybelsus (oral tablet for type 2 diabetes) [3]: - Starting dose: 3 mg once daily for 30 days - Increase to: 7 mg once daily - If additional control is needed: 14 mg once daily - Must be taken on an empty stomach with up to 4 oz of plain water only, at least 30 minutes before any food, drink, or other oral medications - Swallow whole — do not split, crush, or chew

Missed dose: If a weekly injection is missed, administer as soon as possible within 5 days. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day ^{[1, 2]}. For Rybelsus, skip the missed dose and take the next dose the following day ^[3].

Semaglutide is a brand-name medication with significant costs, though options exist to reduce out-of-pocket expenses ^{[14, 17]}.

Typical retail pricing (without insurance, approximate 2025 prices): - Ozempic: $900-$1,100 per month (4-week supply) - Wegovy: $1,300-$1,500 per month - Rybelsus: $900-$1,000 per month

Insurance coverage: Most commercial insurance plans cover Ozempic and Rybelsus for type 2 diabetes with prior authorization ^[9]. Coverage for Wegovy (weight management) is less consistent — some plans cover it, while others exclude weight loss medications. Medicare Part D covers Ozempic and Rybelsus for diabetes but added Wegovy coverage for weight loss in 2025.

Manufacturer savings programs: Novo Nordisk offers the Ozempic and Wegovy savings cards for commercially insured patients, which may reduce copays to as low as $25 for up to 24 months ^[14]. These programs are not available for government-insured patients (Medicare, Medicaid, Tricare).

Generic availability: As of early 2025, no generic semaglutide is FDA-approved in the United States ^[17]. Compounding pharmacies have offered compounded semaglutide, but FDA has raised safety concerns about these products ^[15]. The first generic competitors are not expected until the late 2020s when key patents expire.

Patient assistance: Novo Nordisk offers the Patient Assistance Program (PAP) for uninsured or underinsured patients who meet income eligibility criteria ^[14].

Semaglutide should not be used during pregnancy ^{[1, 2, 3]}. Animal studies have shown that semaglutide caused adverse developmental effects (embryo lethality and structural abnormalities) in rats and rabbits at doses below the maximum recommended human dose ^[1]. There are no adequate and well-controlled studies in pregnant women.

Before pregnancy: Discontinue semaglutide at least 2 months before a planned pregnancy due to its long elimination half-life (approximately 1 week) ^{[1, 2]}. Use effective contraception during treatment and for at least 2 months after the last dose.

During pregnancy: If pregnancy occurs during treatment, discontinue semaglutide immediately and inform your healthcare provider ^{[1, 2]}.

Breastfeeding: It is not known whether semaglutide is excreted in human breast milk ^[1]. Semaglutide was present in the milk of lactating rats. Given the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother ^{[1, 13]}. Discuss the risks and benefits with your healthcare provider.

Semaglutide is currently available only as brand-name products manufactured by Novo Nordisk ^[17]. There is no FDA-approved generic version as of early 2025.

Brand-name formulations: - Ozempic (semaglutide injection): FDA-approved for type 2 diabetes (2017). Available as prefilled injection pens in 0.25 mg/0.5 mg, 1 mg, and 2 mg strengths ^[1]. - Wegovy (semaglutide injection): FDA-approved for chronic weight management (2021). Available as prefilled pens in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg strengths ^[2]. - Rybelsus (semaglutide tablets): FDA-approved for type 2 diabetes (2019). Available as 3 mg, 7 mg, and 14 mg oral tablets — the first oral GLP-1 receptor agonist ^[3].

Generic timeline: Novo Nordisk holds multiple patents on semaglutide, including formulation and manufacturing patents extending into the late 2020s and beyond ^[17]. Generic competitors (biosimilars for the injectable forms) are not expected to reach the U.S. market until these patents expire or are successfully challenged.

Compounded semaglutide: During drug shortages, some compounding pharmacies produced compounded semaglutide. However, the FDA has warned that these products have not undergone the same safety and efficacy testing as approved products and may pose risks ^[15].